David Padgett, DO
Pain Medicine · Danville, CANPI 1699730374
Payments from drug & device makers
Across 18 payments — averaging $33.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$146
- Biodelivery Sciences International, Inc.$132
- Daiichi Sankyo Inc.$81
- GRT US Holding, Inc.$56
- Bioventus LLC$34
- Merz North America, Inc.$33
- plus $123 from 6 others
What the payments were for
- Food & beverage$605100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 2 | $146 |
| Biodelivery Sciences International, Inc. | 3 | $132 |
| Daiichi Sankyo Inc. | 1 | $81 |
| GRT US Holding, Inc. | 2 | $56 |
| Bioventus LLC | 2 | $34 |
| Merz North America, Inc. | 1 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Electronic Waveform Lab, Inc. | 1 | $24 |
| Nalu Medical, Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $19 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$605 in reported general payments places this provider in the 30th percentile of 840 pain medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 31 | $496 |
| Baclofen | 17 | $331 |
| Tramadol Hcl | 25 | $293 |
| Meloxicam | 20 | $260 |
Paid to pharmacies, not to this prescriber.
Other pain medicine in Danville
- Eric GrigsbyNapa$3.2M
- Jason PopeSanta Rosa$2.8M
- Javid GhandehariSanta Monica$2.7M
- Alexander HerselThousand Oaks$2.1M
- Krishnan ChakravarthyTemecula$1.9M
- Kasra AmirdelfanWalnut Creek$1.7M
- Ramana NaiduLarkspur$1.6M
- Foead GeulaStudio City$1.3M
- Xiang QianRedwood City$941K
- Jacqueline WeisbeinNapa$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.